Updates
Addiction Experts Sound Alarm as Overdoses Rise Over COVID-19
While the world has been focused on the COVID-19 pandemic, the existing overdose epidemic has continued to skyrocket, with a record high 70,000 deaths in 2019. Nora Voklow, M.D., Director of the National Institute on Drug Abuse (NIDA), explains, “We do not yet have...
HHS Expands Access to Treatment for Opioid Use Disorder
The Department of Health and Human Services (HHS) has announced it is eliminating the medication-assisted treatment (MAT) waiver requirement for some physicians. HHS will publish Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use...
Combination Treatment for Methamphetamine Use Disorder Shows Promise in NIH Study
A combination of two medications, injectable naltrexone and oral bupropion, was safe and effective in treating adults with moderate or severe methamphetamine use disorder. That’s the finding of a double-blind, placebo-controlled Phase III clinical trial, published in...
New CDC Training and Resources for Safer Opioid Prescribing
Centers for Disease Control and Prevention (CDC) released a new suite of training tools and resources to help clinicians and healthcare executives apply CDC Guideline for Prescribing Opioids for Chronic Pain in clinical settings: Addressing the Opioid Overdose...
CDC Health Advisory: Increase in Fatal Drug Overdoses Across U.S. Driven by Synthetic Opioids Before & During COVID-19 Pandemic
The purpose of this Health Alert Network (HAN) Advisory is to alert public health departments, healthcare professionals, first responders, harm reduction organizations, laboratories, and medical examiners and coroners to — (1) substantial increases in drug overdose...
NC Statewide Overdose Surveillance Reports for November 2020
The Injury and Violence Prevention Branch of the Division of Public Health recently updated data on opioid-related overdose and unintentional med/drug overdose with potential for abuse emergency department visits reports (NC DETECT). Overdose Involving Medication or...
Target Audience
Sessions 1-3: Physicians, nurse practitioners or other advanced practice nurses, PAs, psychologists, social workers, clinical administrators and healthcare teams.
Sessions 4-6: Physicians, nurse practitioners or other advanced practice nurses, PAs, and healthcare teams.
Date: Monday, January 25, 2021
Time: 5:00 pm – 9:30 pm PT
What: Live portion of 8-hour MAT waiver course
Sponsoring organization: American Osteopathic Academy of Addiction Medicine (AOAAM)
Course Director: William Morrone, DO
How it Works: When you have completed the entire course, you will receive a certificate of completion. Physicians will then be able to apply for the waiver to prescribe buprenorphine. All other eligible providers can apply for the waiver after completing an additional 16-hour course here for advanced practice nurses and here for PAs.
Target Audience
Sessions 1-3: Physicians, nurse practitioners or other advanced practice nurses, PAs, psychologists, social workers, clinical administrators and healthcare teams.
Sessions 4-6: Physicians, nurse practitioners or other advanced practice nurses, PAs, and healthcare teams.
Learn more about our conferences and educational opportunities
Addiction Medicine Spring and Fall Conferences provide up-to-date substance use related education, applicable across general medical as well as addiction specialty practices.